<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Alexion Pharmaceuticals, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=21161></link><description><![CDATA[Alexion Pharmaceuticals, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 29 Apr 2026 15:12:25 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2016/03/3554153577_20160302115152_7387966600.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service]]></title><link>https://www.newswire.co.kr/newsRead.php?no=859499</link><description><![CDATA[NEW HAVEN, Conn.--(Business Wire/Korea Newswire)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced that more than 1,300 employees are rallying together in support of community service initiatives focused on health, wellness, and education as part of the Company’s second annual Global Day of Service. Alexion has partnered with non-profit organizations in nearly 30 of the Company’s local com...]]></description><pubDate>Fri, 10 Nov 2017 10:09:05 +0900</pubDate></item><item><title><![CDATA[Alexion Employees Volunteer Together in Company’s First Global Day of Service]]></title><link>https://www.newswire.co.kr/newsRead.php?no=835878</link><description><![CDATA[NEW HAVEN, Conn.--(Business Wire/Korea Newswire)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that more than 1,500 employees around the world are volunteering in their respective communities as part of the Company’s first Global Day of Service. For this inaugural event, Alexion employees are partnering with local non-profit organizations to participate in service projects focuse...]]></description><pubDate>Fri, 23 Sep 2016 19:30:00 +0900</pubDate></item><item><title><![CDATA[Alexion Employees Across the Globe Join Together to Support Rare Disease Day 2016]]></title><link>https://www.newswire.co.kr/newsRead.php?no=819215</link><description><![CDATA[NEW HAVEN, Conn.--(Business Wire/Korea Newswire)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) joins the worldwide rare disease community in honoring the ninth annual international Rare Disease Day. Rare Disease Day takes place the last day of February each year and is dedicated to raising awareness of rare diseases and their impact on patients and families. Alexion employees will participate in...]]></description><pubDate>Wed, 02 Mar 2016 11:45:00 +0900</pubDate></item><item><title><![CDATA[알렉시온, 전 세계 임직원과 함께 2016년 희귀질환의 날 기념]]></title><link>https://www.newswire.co.kr/newsRead.php?no=819217</link><description><![CDATA[뉴헤이븐, 코네티컷--(Business Wire/뉴스와이어)--알렉시온 제약(Alexion Pharmaceuticals, Inc.) (Nasdaq:ALXN)이 전 세계 희귀질환 공동체와 함께 제9회 세계 희귀질환의 날(Rare Disease Day)을 기념했다. 세계 희귀질환의 날은 매년 2월 마지막 날에 열리며, 희귀질환과 그 환자 및 가족에 대한 사회적 인식을 높이기 위해 마련됐다. 알렉시온 임직원은 전세계에서 열리는 행사에 참석해 희귀질환은 지속적인 연구와 공...]]></description><pubDate>Wed, 02 Mar 2016 11:45:00 +0900</pubDate></item><item><title><![CDATA[New Data Presented at ASH Annual Meeting Enhance Understanding of PNH and aHUS to Provide Optimal Care for Patients with These Life-threatening Disorders]]></title><link>https://www.newswire.co.kr/newsRead.php?no=727743</link><description><![CDATA[CHESHIRE, Conn.--(Business Wire/Korea Newswire)--CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers presented data from clinical trials demonstrating the clinical benefits of chronic Soliris® (eculizumab) treatment in patients with atypical hemolytic uremic syndrome (aHUS) as well as new patient registry data providing further insig...]]></description><pubDate>Thu, 12 Dec 2013 08:40:00 +0900</pubDate></item><item><title><![CDATA[ASH연례 회의에서 발표된 새로운 데이터, PNH와 aHUS에 대한 이해 도와 이 생명에 위협을 주는 장애에 대한 최적의 치료 제공]]></title><link>https://www.newswire.co.kr/newsRead.php?no=727744</link><description><![CDATA[체셔, 코네티컷.--(Business Wire/뉴스와이어)--알렉시온 제약 (Alexion Pharmaceuticals, Inc., 나스닥: ALXN)은 오늘 연구자들이 임상실험을 통해 만성적인 솔리리스 (솔리리스® -eculizumab)치료가 용혈성요독증후군 (atypical hemolytic uremic syndrome, aHUS) 환자에 가져다 주는 임상적인 혜택과 발작야간혈색소증(paroxysmal nocturnal hemoglobinuria, PNH)환자를 위한 최적의 케어에 대한 깊은 통찰을 제공하는 ...]]></description><pubDate>Thu, 12 Dec 2013 08:40:00 +0900</pubDate></item></channel></rss>